Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 14/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335352 | 1.00 | CHEK2 (0.78) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL12390553 | 0.89 | CHEK2 (0.79) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL2331785 | 0.88 | CHEK2 (0.78) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL2331777 | 0.88 | CHEK2 (0.78) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL2332513 | 0.88 | CHEK2 (1.00) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL2332509 | 0.88 | CHEK2 (1.00) | CHEK2CHEK1POLBTSHRMAPK1 | |
| SCHEMBL1084334 | 0.80 | CYP2D6 (0.57) | CHEK2TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2330902 | 0.76 | CHEK2 (1.00) | CHEK2CHEK1 | |
| SCHEMBL2330896 | 0.76 | CHEK2 (1.00) | CHEK2CHEK1 | |
| SCHEMBL4092209 | 0.76 | POLB (0.53) | CHEK2POLBTSHRMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | CHEK2 1/4885CHEK1 2/4885POLB 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.